Bridge City Capital LLC Increases Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Bridge City Capital LLC raised its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 28.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 103,809 shares of the company’s stock after acquiring an additional 22,773 shares during the period. Bridge City Capital LLC owned approximately 0.18% of Harmony Biosciences worth $3,572,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of HRMY. Citigroup Inc. increased its position in Harmony Biosciences by 9.8% in the third quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock worth $7,114,000 after purchasing an additional 15,859 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Harmony Biosciences by 364.0% in the 3rd quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock worth $3,199,000 after buying an additional 62,729 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Harmony Biosciences by 68.4% during the third quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock worth $9,217,000 after acquiring an additional 93,622 shares during the last quarter. StoneX Group Inc. bought a new position in shares of Harmony Biosciences during the 3rd quarter valued at approximately $755,000. Finally, Barclays PLC raised its holdings in Harmony Biosciences by 110.9% during the 3rd quarter. Barclays PLC now owns 76,862 shares of the company’s stock valued at $3,074,000 after buying an additional 40,416 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $35.28 on Friday. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The stock has a market cap of $2.02 billion, a PE ratio of 16.72, a P/E/G ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock has a 50 day moving average price of $36.42 and a 200 day moving average price of $35.58.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. The company had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences’s revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.45 EPS. Equities research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HRMY shares. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, February 25th. HC Wainwright dropped their price objective on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Mizuho increased their target price on Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price for the company. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $53.33.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.